TLX Healthcare

Telix Pharmaceuticals Limited

$9.03-0.22%

Price as of close on Nov 3, 2026 · Financials updated Sep 30, 2026

Basics

Sector: Healthcare
Industry: Biotechnology
Country: Australia
Market cap: 3.1B USD
Enterprise value: 7.5B USD
Full-time employees: 1,120

Overall health

Strength: growing faster than most peersgrowing faster than peers
Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings
Drawback: higher risk than most peers: less short-term liquidity (current ratio 1.43 vs a peer median of 2.59) and more debt relative to equity (0.98× vs a peer median of 0.22×)higher risk: less liquidity (current ratio 1.43 vs peers 2.59) and more debt vs equity (0.98× vs peers 0.22×)
About average: profitability

Ranks #708 of 1,157 healthcare companies (bottom 39%)

See how it ranks against its peers

Worth knowing

Earnings slid into a loss. Loss per share this year after a profit last year.
Telix Pharmaceuticals made a loss per share in its latest year after a profit the year before.
Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.
Relative to its free cash flow, Telix Pharmaceuticals looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.
Not profitable yet. Reported a loss in the 12 months to December 2025.
Telix Pharmaceuticals reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.
Financials may be out of date. Latest financial period ended 10 months ago.
The latest financial period we have ended 10 months ago, so the scores may not reflect recent results.

StockQuotient Score

46/ 100

Oct 5 46 → Nov 4 46

Valuation

Is the price right?

31/100

Weak

3/3 inputs reported · High confidence

Why

Weaker than most peers on:

▼ Earnings yield
▼ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-0.1%

SEC filings (IFRS mapped) · 12 months to Dec 2025Negative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yield0.8%

SEC filings (IFRS mapped) · 12 months to Dec 2025Reported value50% base weight · Z-score -0.80Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield-0.7%

SEC filings (IFRS mapped) · 12 months to Dec 2025 · operating cash flow − capital spendingNegative (a loss or cash outflow), so it counts as zero whatever the share price20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield6.8%

SEC filings (IFRS mapped) · latest balance sheetReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

91/100

Strong

3/3 inputs reported · High confidence

Why

Stronger than most peers on:

▲ 3-yr revenue
▲ Revenue growth

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growthUnavailable

Earnings per share turned from a profit to a loss33% base weight · Z-score -1.99Sector median: 0.0976 · MAD: 0.2991

3-year revenue growth94.7%

Yahoo Finance fallback · SEC figure unavailable or out of date · 3 fiscal years to Dec 2025Outlier capped at sector 5th/95th percentile33% base weight · Z-score 8.59Sector median: 0.0584 · MAD: 0.0840

Revenue growth55.6%

SEC filings (IFRS mapped) · 12 months to Dec 2025Reported value33% base weight · Z-score 5.08Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

41/100

Moderate

3/3 inputs reported · High confidence

Why

Held back by:

▼ ROA

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin3.7%

SEC filings (IFRS mapped) · 12 months to Dec 2025Reported value33% base weight · Z-score -0.28Sector median: 0.0706 · MAD: 0.1217

Return on assets-0.6%

SEC filings (IFRS mapped) · 12 months to Dec 2025Reported value33% base weight · Z-score -0.42Sector median: 0.0166 · MAD: 0.0537

Return on invested capital3.5%

SEC filings (IFRS mapped) · 12 months to Dec 2025Reported value33% base weight · Z-score -0.12Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin53.1%

SEC filings (IFRS mapped) · 12 months to Dec 2025Reported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity-1.7%

SEC filings (IFRS mapped) · 12 months to Dec 2025Reported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Higher

Higher relative risk

3/3 inputs reported · High confidence

Why

Weaker than most peers on:

▼ Debt / equity
▼ Current ratio

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta0.60

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score 0.06Sector median: 0.6250 · MAD: 0.3380

Current ratio1.43×

SEC filings (IFRS mapped) · latest balance sheetReported value33% base weight · Z-score -0.84Sector median: 2.5860 · MAD: 1.3850

Debt / equity0.98×

SEC filings (IFRS mapped) · latest balance sheetReported value33% base weight · Z-score -3.70Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Telix Pharmaceuticals

Is Telix Pharmaceuticals getting weaker?: A comparison of its latest SEC filing with the previous one isn't available yet. Its overall score is unchanged at 46/100 since Oct 28, 2026.
How is Telix Pharmaceuticals valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 31/100 against 1,393 healthcare peers. Earnings yield -0.1% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -0.1% vs peers 1.5% (weaker than 100% of peers).
Is Telix Pharmaceuticals growing?: Yes, faster than most of its peers. Growth scores 91/100 against 1,393 healthcare peers. 3-year revenue growth 94.7% vs a peer median of 5.8% (stronger than 95% of peers).3-year revenue growth 94.7% vs peers 5.8% (stronger than 95% of peers).
How profitable is Telix Pharmaceuticals?: About as profitable as its peers. Profitability scores 41/100 against 1,393 healthcare peers. Return on assets -0.6% vs a peer median of 1.7% (weaker than 61% of peers).Return on assets -0.6% vs peers 1.7% (weaker than 61% of peers).
How risky is Telix Pharmaceuticals?: Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Debt / equity 0.98× vs a peer median of 0.22× (weaker than 81% of peers).Debt / equity 0.98× vs peers 0.22× (weaker than 81% of peers). A relative measure, not a bankruptcy probability.

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2023	FY 2024	FY 2025	Change
Gross margin	62.9%	65.1%	53.1%	▼ 12 pts
Operating margin	3.3%	10.7%	3.7%	▼ 7.0 pts
Net margin	1.3%	6.5%	-0.9%	▼ 7.4 pts
Return on assets (ROA)	1.5%	3.6%	-0.6%	▼ 4.2 pts
Return on equity (ROE)	4.1%	9.5%	-1.7%	▼ 11 pts
Free cash flow margin	2.4%	3.6%	-5.3%	▼ 8.9 pts
Current ratio	1.42×	2.78×	1.43×	▼ 49%
Quick ratio	1.31×	2.66×	1.27×	▼ 52%
Debt to equity	0.06×	1.00×	0.98×	▼ 2.7%
Interest coverage	113.48×	862.14×	164.51×	▼ 81%

TLX price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Strength: growing faster than most peersgrowing faster than peers

Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

Drawback: higher risk than most peers: less short-term liquidity (current ratio 1.43 vs a peer median of 2.59) and more debt relative to equity (0.98× vs a peer median of 0.22×)higher risk: less liquidity (current ratio 1.43 vs peers 2.59) and more debt vs equity (0.98× vs peers 0.22×)

About average: profitability

Ranks #708 of 1,157 healthcare companies (bottom 39%)

See how it ranks against its peers

Worth knowing

Earnings slid into a loss. Loss per share this year after a profit last year.

Telix Pharmaceuticals made a loss per share in its latest year after a profit the year before.

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.

Relative to its free cash flow, Telix Pharmaceuticals looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Not profitable yet. Reported a loss in the 12 months to December 2025.

Telix Pharmaceuticals reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

Financials may be out of date. Latest financial period ended 10 months ago.

The latest financial period we have ended 10 months ago, so the scores may not reflect recent results.

Questions investors ask about Telix Pharmaceuticals

Is Telix Pharmaceuticals getting weaker?

A comparison of its latest SEC filing with the previous one isn't available yet. Its overall score is unchanged at 46/100 since Oct 28, 2026.

How is Telix Pharmaceuticals valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 31/100 against 1,393 healthcare peers. Earnings yield -0.1% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -0.1% vs peers 1.5% (weaker than 100% of peers).

Is Telix Pharmaceuticals growing?

Yes, faster than most of its peers. Growth scores 91/100 against 1,393 healthcare peers. 3-year revenue growth 94.7% vs a peer median of 5.8% (stronger than 95% of peers).3-year revenue growth 94.7% vs peers 5.8% (stronger than 95% of peers).

How profitable is Telix Pharmaceuticals?

About as profitable as its peers. Profitability scores 41/100 against 1,393 healthcare peers. Return on assets -0.6% vs a peer median of 1.7% (weaker than 61% of peers).Return on assets -0.6% vs peers 1.7% (weaker than 61% of peers).

How risky is Telix Pharmaceuticals?

Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Debt / equity 0.98× vs a peer median of 0.22× (weaker than 81% of peers).Debt / equity 0.98× vs peers 0.22× (weaker than 81% of peers). A relative measure, not a bankruptcy probability.

Key ratios

FY 2023

FY 2024

FY 2025

Change

Gross margin

62.9%

65.1%

53.1%

▼ 12 pts

Operating margin

3.3%

10.7%

3.7%

▼ 7.0 pts

Net margin

1.3%

6.5%

-0.9%

▼ 7.4 pts

Return on assets (ROA)

1.5%

3.6%

-0.6%

▼ 4.2 pts

Return on equity (ROE)

4.1%

9.5%

-1.7%

▼ 11 pts

Free cash flow margin

2.4%

3.6%

-5.3%

▼ 8.9 pts

Current ratio

1.42×

2.78×

1.43×

▼ 49%

Quick ratio

1.31×

2.66×

1.27×

▼ 52%

Debt to equity

0.06×

1.00×

0.98×

▼ 2.7%

Interest coverage

113.48×

862.14×

164.51×

▼ 81%